Previous 10 | Next 10 |
2024-05-14 06:35:00 ET Investors have put their hopes in Moderna 's (NASDAQ: MRNA) next potential product, a respiratory syncytial virus (RSV) vaccine. That's because it represents a new revenue stream for a company that until now has relied on just one product, and a product strugg...
2024-05-13 08:45:00 ET Equities have been on a bull run for well over a year. Though it might be tempting to invest in stocks that have largely been in tandem with the broader market, it's even better to consider those companies that have failed to keep pace, provided they display solid ups...
CAMBRIDGE, MA / ACCESSWIRE / May 13, 2024 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conferences: Bernstein's 40th Annual Strategic Decisions Conference (SDC), on Friday, May 31 st at 10:00am ET Jefferies Healthcare Conference, on Thurs...
2024-05-12 09:25:00 ET Moderna (NASDAQ: MRNA) and OpenAI are collaborating to bring artificial intelligence (AI) to every level of the biotech's operations, and the implications could perhaps be significant for investors. If the lofty claims made by others in the biotech industry ar...
2024-05-10 11:15:35 ET More on Novavax Novavax Q1 2024 Earnings Preview: Success In New Commercial COVID Markets Unlikely Novavax, Inc. (NVAX) TD Cowen's 44th Annual Health Care Conference - (Transcript) Novavax: Another Day Older And Deeper In Novavax surges...
2024-05-10 07:17:32 ET More on Moderna Moderna, Inc. (MRNA) Q1 2024 Earnings Call Transcript Moderna, Inc. 2024 Q1 - Results - Earnings Call Presentation Moderna Investors Should Beware Patent-Dispute Fallout Moderna to seek parity for RSV shot as rivals lead...
U.S. FDA has informed Moderna that due to administrative constraints, the agency will not complete its review of mRNA-1345 by the PDUFA date of May 12, 2024 Agency has indicated it expects to complete the review by end of May CAMBRIDGE, MA / ACCESSWIRE / May 10, 2024 / Moderna, Inc. (N...
2024-05-09 13:22:28 ET More on Novo Nordisk The FTC Cracks Down On Novo Nordisk's Ozempic Novo Nordisk A/S 2024 Q1 - Results - Earnings Call Presentation Novo Nordisk A/S (NVO) Q1 2024 Earnings Call Transcript Catalent, Novo Nordisk receive FTC request for mo...
2024-05-09 09:05:00 ET Five years ago, pharmaceutical company Moderna (NASDAQ: MRNA) was mostly unknown. It was developing vaccines that induce human immune cells to more effectively fight disease. But the science of DNA-based drugs was on the experimental fringe of the biopharma la...
2024-05-08 11:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
News, Short Squeeze, Breakout and More Instantly...
On Friday, the FDA approved Moderna Inc’s (NASDAQ:MRNA) mRESVIA (mRNA-1345), an mRNA respiratory syncytial virus (RSV) vaccine to protect adu...
2024-05-31 15:30:03 ET RBC Capital analyst issues OUTPERFORM recommendation for MRNA on May 31, 2024 01:55PM ET. The previous analyst recommendation was Outperform. MRNA was trading at $141.9 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
2024-05-31 15:00:07 ET Luca Issi from RBC Capital issued a price target of $160.00 for MRNA on 2024-05-31 13:55:00. The adjusted price target was set to $160.00. At the time of the announcement, MRNA was trading at $141.83. The overall price target consensus is at $158.4...